Levosulpiride

Template:Chembox E number

Levosulpiride

Names
IUPAC name N-[[(2S)-1-Ethylpyrrolidin-2-yl]methyl]-2-methoxy-5-sulfamoylbenzamide
Identifiers
CAS Number	23672-07-3 Y
3D model (JSmol)	Interactive image
ChEBI	CHEBI:4119 N
ChEMBL	ChEMBL267044 N
ChemSpider	599749 N
ECHA InfoCard
KEGG	D07312 Y
PubChem CID	688272
InChI InChI=1S/C15H23N3O4S/c1-3-18-8-4-5-11(18)10-17-15(19)13-9-12(23(16,20)21)6-7-14(13)22-2/h6-7,9,11H,3-5,8,10H2,1-2H3,(H,17,19)(H2,16,20,21)/t11-/m0/s1 N Key: BGRJTUBHPOOWDU-NSHDSACASA-N N InChI=1/C15H23N3O4S/c1-3-18-8-4-5-11(18)10-17-15(19)13-9-12(23(16,20)21)6-7-14(13)22-2/h6-7,9,11H,3-5,8,10H2,1-2H3,(H,17,19)(H2,16,20,21)/t11-/m0/s1 Key: BGRJTUBHPOOWDU-NSHDSACABD
SMILES CCN1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC
Properties
Chemical formula	C15H23N3O4S
Molar mass	341.43 g·mol−1

WikiDoc Resources for Levosulpiride
Articles
Most recent articles on Levosulpiride Most cited articles on Levosulpiride Review articles on Levosulpiride Articles on Levosulpiride in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Levosulpiride Images of Levosulpiride Photos of Levosulpiride Podcasts & MP3s on Levosulpiride Videos on Levosulpiride
Evidence Based Medicine
Cochrane Collaboration on Levosulpiride Bandolier on Levosulpiride TRIP on Levosulpiride
Clinical Trials
Ongoing Trials on Levosulpiride at Clinical Trials.gov Trial results on Levosulpiride Clinical Trials on Levosulpiride at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Levosulpiride NICE Guidance on Levosulpiride NHS PRODIGY Guidance FDA on Levosulpiride CDC on Levosulpiride
Books
Books on Levosulpiride
News
Levosulpiride in the news Be alerted to news on Levosulpiride News trends on Levosulpiride
Commentary
Blogs on Levosulpiride
Definitions
Definitions of Levosulpiride
Patient Resources / Community
Patient resources on Levosulpiride Discussion groups on Levosulpiride Patient Handouts on Levosulpiride Directions to Hospitals Treating Levosulpiride Risk calculators and risk factors for Levosulpiride
Healthcare Provider Resources
Symptoms of Levosulpiride Causes & Risk Factors for Levosulpiride Diagnostic studies for Levosulpiride Treatment of Levosulpiride
Continuing Medical Education (CME)
CME Programs on Levosulpiride
International
Levosulpiride en Espanol Levosulpiride en Francais
Business
Levosulpiride in the Marketplace Patents on Levosulpiride
Experimental / Informatics
List of terms related to Levosulpiride

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

N verify (what is ^YN ?) Infobox references

Levosulpiride is a substituted benzamide antipsychotic, reported to be a selective antagonist of dopamine D₂ receptor activity on both central and peripheral levels. It is an atypical neuroleptic and a prokinetic agent. Levosulpiride is also claimed to have mood elevating properties. Levosulpiride is used in the treatment of psychoses, particularly negative symptoms of schizophrenia, anxiety disorders, dysthymia, vertigo, dyspepsia, irritable bowel syndrome and premature ejaculation.

Chemically, it is the (S)-enantiomer of sulpiride.

Side effect

Side effects include amenorrhoea, gynaecomastia, galactorrhoea, changes in libido, and neuroleptic malignant syndrome. It also effects GI motility may be antagonized by anticholinergic agents, narcotics and analgesics.

Mechanism of action

In contrast to most other neuroleptics which block both dopamine D₁ and D₂ receptors, sulpiride is more selective and acts primarily as a dopamine D₂ antagonist. Sulpiride appears to lack effects on norepinephrine, acetylcholine, serotonin, histamine, or gamma-aminobutyric acid (GABA) receptors.

Pharmacodynamics

Sulpiride is a substituted benzamide derivative and a selective dopamine D₂ antagonist with antipsychotic and antidepressant activity. Other benzamide derivatives include metoclopramide, tiapride, and sultopride.